Apocynin combined with drugs as coadjuvant could be employed to prevent and/or treat the chronic kidney disease

References

• Organización Panamericana de la Salud OMdlS, Sociedad Latinoamericana de Nefrología. Llaman a prevenir la enfermedad renal y a mejorar el acceso al tratamiento: Organización Panamericana de la Salud Organización Mundial de la Salud; 2015.
   Google Scholar
• Sellarés VL. Enfermedad renal crónica. Nefrología. 2010;25:3126–3127.
   Google Scholar
• K/DOQI National kidney foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2012;39:S1–S266.
   Google Scholar
• KDIGO 2012. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1–150.
   Web of Science ®Google Scholar
• Gorostidi M. Spanish Society of Nephrology document on KDIGO guidelines for the assessment and treatment of chronic kidney disease. Nefrología. 2014;34:302–316. Incluir la referencia de la guia KDIGO 2013 original.
   PubMed Web of Science ®Google Scholar
• Tamay CF, Quintana PJC, Trujillo FJG, et al. A review of the impact of oxidative stress and some antioxidant therapies on renal damage. Renal Failure. 2015;38:1–5.
   PubMed Web of Science ®Google Scholar
• Puchades MMJ, et al. Estudio del estrés oxidativo en enfermedad renal avanzada. Nefrología. 2009;29:464–473.
   PubMedGoogle Scholar
• Couchoud C, Moranne O, Frimat L, et al. Associations between comorbidities, treatment choice and outcome in the elderly with end-stage renal disease. Nephrol Dial Transplant. 2007;22:3246–3254.
   PubMed Web of Science ®Google Scholar
• Valko M, Leibfritz D, Moncol J, et al. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39:44–84.
   PubMed Web of Science ®Google Scholar
• Joshi S, Peck AB, Khan SR. NADPH oxidase as a therapeutic target for oxalate induced injury in kidneys. Oxid Med Cell Longev. 2013;1:1–18.
   Google Scholar
• Streeter J, Thiel W, Brieger K, et al. Opportunity nox: the future of NADPH oxidases as therapeutic targets in cardiovascular disease. Cardiovasc Ther. 2013;31:125–137.
   PubMed Web of Science ®Google Scholar
• Li JM, Shah AM. Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am J Physiol Regul Integr Comp Physiol. 2004;287:R1014–R1R30.
   PubMed Web of Science ®Google Scholar
• Mora M, Weïwer M, Yu J, et al. Inhibition of human vascular NADPH oxidase by apocynin derived oligophenols. Bioorg Med Chem. 2009;17:5146–5152.
   PubMed Web of Science ®Google Scholar
• Kuzkaya N, Weissmann N, Harrison DG, et al. Interactions of peroxinitrite, tetrahydrobiopterin, ascorbic acid, and thiols. J Biol Chem. 2003;278:22546–22554.
   PubMed Web of Science ®Google Scholar
• Lahera V, Vazquez S, De las Heras N, et al. Angiotensina II e hipertensión arterial: consecuencias del antagonismo de sus receptores. Hipoertensión. 2000;17:22–29.
   Google Scholar
• Serna F. Novedades en el sistema renina-angiotensina. insuficiencia CARDIACA. 2014;9:16–24.
   Google Scholar
• Godbole AS, Xiao L, Guo X, et al. NADPH oxidase has a directional response to shear stress. Am J Physiol Heart Circ Physiol. 2009;296:H152–H1H8.
   PubMed Web of Science ®Google Scholar
• Hamilton CA, Brosnan MJ, Benna SA, et al. NAD(P)H oxidase inhibition improves endothelial function in rat and human blood vessels. Hipertension. 2002;40:755–762.
   PubMed Web of Science ®Google Scholar
• Ximenes VF, Kanegae MP, Rissato SR, et al. The oxidation of apocynin catalyzed by myeloperoxidase: proposal for NADPH oxidase inhibition. Arch Biochem Biophys. 2007;457:134–141.
   PubMed Web of Science ®Google Scholar
• Care and Use of Laboratory Animals of the Sección de Estudios de Posgrado e Investigación of the Escuela Superior de Medicina of the Instituto Politécnico Nacional. 2016.
   Google Scholar
• Norma Oficial Mexicana. Technical specifications for the production, care and use of laboratory animals. NOM-062-ZOO-1999. 1999:1–58.
   Google Scholar
• Norma Oficial Mexicana NOM-087-ECOL-SSA1-2002. Environmental protection-environmental health-biological-infectious hazardous waste. Classification and management specifications. 2002:1–20.
   Google Scholar
• Yin J. MnTBAP therapy attenuates renal fibrosis in mice with 5/6 nephrectomy. Oxid Med Cell Longev. 2016;1:1–10.
   Google Scholar
• Mahfouz R, Sharma R, Lackner J, et al. Evaluation of chemiluminescence and flow cytometry as tools in assessing production of hydrogen peroxide and superoxide anion in human spermatozoa. Am Soc Reprod Med. 2009;92:819–827.
   Google Scholar
• Valladares MB, De la Cruz YLG, Franch NF, et al. Antioxidant defenses in the experimental chronic renal failure. Rev Cubana Invest Bioméd. 2011;30:292–300.
   Google Scholar
• Gava AL, Feitas FP, Balarini CM, et al. Effects of 5/6 nephrectomy on renal function and blood pressure in mice. Int J Physiol Pathophysiol Pharmacol. 2012;4:167–173.
   PubMedGoogle Scholar
• Rabêlo LA, Nunes SV, Sá da FLJ, et al. Redox unbalance: NADPH oxidase as therapeutic target in blood pressure control. Arq Bras Cardiol. 2010;94:643–651.
   PubMed Web of Science ®Google Scholar
• Arellano MMG, Vargas RH, Del Valle ML, et al. Prevention of renal injury and endothelial dysfunction by chronic L-arginine and antioxidant treatment. Ren Fail. 2011;33:47–53.
   PubMed Web of Science ®Google Scholar
• Lara TJ. Oxydative stress, endothelial dysfunction and atheroesclerosis. An Fac Med. 2014;75:351–352.
   Google Scholar
• Mennuni S, Rubattu S, Pierelli G, et al. Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage. J Hum Hypertens. 2014;28:74–79.
   PubMed Web of Science ®Google Scholar
• Feldstein CA, Romero JC. El sistema renina angiotensina en la hipertensión esencial. Rev latinoam hiperte 2007;2:49–58.
   Google Scholar